Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.73 Million USD | -21.32% |
| 2022 | 11.84 Million USD | -12.89% |
| 2021 | 13.59 Million USD | 60.96% |
| 2020 | 8.44 Million USD | -11.05% |
| 2019 | 9.49 Million USD | 41.98% |
| 2018 | 6.68 Million USD | 20.64% |
| 2017 | 5.54 Million USD | 47.38% |
| 2016 | 3.76 Million USD | -39.26% |
| 2015 | 6.19 Million USD | 750.43% |
| 2014 | 728.2 Thousand USD | -21.54% |
| 2013 | 928.08 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.4 Million USD | -35.55% |
| 2024 Q1 | 2.19 Million USD | 7.99% |
| 2023 Q3 | 2.23 Million USD | -1.27% |
| 2023 FY | 9.31 Million USD | -21.32% |
| 2023 Q1 | 2.79 Million USD | 26.11% |
| 2023 Q2 | 2.26 Million USD | -19.2% |
| 2023 Q4 | 2.03 Million USD | -8.78% |
| 2022 Q2 | 3.11 Million USD | -15.74% |
| 2022 Q1 | 3.69 Million USD | -1.2% |
| 2022 FY | 11.84 Million USD | -12.89% |
| 2022 Q4 | 2.21 Million USD | -21.24% |
| 2022 Q3 | 2.81 Million USD | -9.41% |
| 2021 FY | 13.59 Million USD | 60.96% |
| 2021 Q2 | 2.99 Million USD | 8.14% |
| 2021 Q1 | 2.76 Million USD | 11.83% |
| 2021 Q3 | 4.09 Million USD | 36.59% |
| 2021 Q4 | 3.73 Million USD | -8.66% |
| 2020 Q1 | 2.47 Million USD | -7.8% |
| 2020 Q3 | 2.27 Million USD | 85.7% |
| 2020 Q4 | 2.47 Million USD | 9.0% |
| 2020 FY | 8.44 Million USD | -11.05% |
| 2020 Q2 | 1.22 Million USD | -50.52% |
| 2019 Q2 | 2.97 Million USD | 123.68% |
| 2019 Q3 | 2.5 Million USD | -15.91% |
| 2019 Q4 | 2.68 Million USD | 7.17% |
| 2019 FY | 9.49 Million USD | 41.98% |
| 2019 Q1 | 1.33 Million USD | -10.36% |
| 2018 Q4 | 1.48 Million USD | 13.36% |
| 2018 Q3 | 1.3 Million USD | -9.57% |
| 2018 Q2 | 1.44 Million USD | -40.81% |
| 2018 Q1 | 2.44 Million USD | 3.71% |
| 2018 FY | 6.68 Million USD | 20.64% |
| 2017 FY | 5.54 Million USD | 47.38% |
| 2017 Q4 | 2.35 Million USD | 46.1% |
| 2017 Q3 | 1.61 Million USD | 82.63% |
| 2017 Q2 | 884.02 Thousand USD | 28.89% |
| 2017 Q1 | 685.88 Thousand USD | -39.93% |
| 2016 Q1 | 737.7 Thousand USD | -33.12% |
| 2016 FY | 3.76 Million USD | -39.26% |
| 2016 Q4 | 1.14 Million USD | 30.95% |
| 2016 Q3 | 872 Thousand USD | -13.64% |
| 2016 Q2 | 1 Million USD | 36.87% |
| 2015 FY | 6.19 Million USD | 750.43% |
| 2015 Q3 | 2.33 Million USD | -1.04% |
| 2015 Q2 | 2.35 Million USD | -0.0% |
| 2015 Q1 | 2.35 Million USD | 1149.44% |
| 2015 Q4 | 1.1 Million USD | -52.72% |
| 2014 Q4 | 188.68 Thousand USD | 0.0% |
| 2014 FY | 728.2 Thousand USD | -21.54% |
| 2013 FY | 928.08 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -17.908% |
| BioQuest Corp. | 89.76 USD | -10840846.97% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 54.033% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 93.085% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | 238.36 Thousand USD | -3982.342% |
| Instadose Pharma Corp. | - USD | -Infinity% |